PMID- 14684148
OWN - NLM
STAT- MEDLINE
DCOM- 20040923
LR  - 20191108
IS  - 0268-960X (Print)
IS  - 0268-960X (Linking)
VI  - 18
IP  - 1
DP  - 2004 Mar
TI  - The therapy of relapsed acute leukaemia in adults.
PG  - 39-63
AB  - Although the cure of acute leukaemia has improved significantly, many patients 
      will still relapse and die. The unraveling of the molecular pathogenesis of acute 
      leukaemia has lead to the identification of new prognostic factors and improved 
      the detection of minimal residual disease. The treatment of relapsed acute 
      leukaemia with chemotherapy remains unsatisfactory. Allogeneic or autologous 
      blood and marrow transplant (BMT) can cure a subset of patients with relapsed 
      acute leukaemia. The identification of the graft-vs-leukaemia (GVL) effect has 
      lead to the development of donor lymphocyte infusions to re-induce remission in 
      patients with relapsed leukaemia after allogeneic BMT and also stimulated the 
      development of the less toxic nonmyeloablative allogeneic transplant approach. 
      The identification of molecular targets of therapy and the development of 
      monoclonal antibody-directed therapy has generated optimism. It is possible that 
      combinations of chemotherapy, molecularly directed therapy, and immunotherapy may 
      be combined to cure an increasing proportion of patients with acute leukaemia.
FAU - Litzow, Mark R
AU  - Litzow MR
AD  - Division of Hematology, Mayo Clinic and Mayo Medical School, 200 First Streeet, 
      SW, Rochester, MN 55905, USA. litzow.mark@mayo.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
SB  - IM
MH  - Acute Disease
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Drug Delivery Systems
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunotherapy
MH  - Leukemia/genetics/*therapy
MH  - Prognosis
MH  - Recurrence
MH  - Salvage Therapy/*methods
RF  - 275
EDAT- 2003/12/20 05:00
MHDA- 2004/09/24 05:00
CRDT- 2003/12/20 05:00
PHST- 2003/12/20 05:00 [pubmed]
PHST- 2004/09/24 05:00 [medline]
PHST- 2003/12/20 05:00 [entrez]
AID - S0268960X03000365 [pii]
AID - 10.1016/s0268-960x(03)00036-5 [doi]
PST - ppublish
SO  - Blood Rev. 2004 Mar;18(1):39-63. doi: 10.1016/s0268-960x(03)00036-5.